Organon & Co.
NYSEOrganon & Co. heads into its July 23 quarterly report with short sellers stepping back and options traders leaning more bullish than they have been in months — a notable setup for a stock that has spent much of the past year under sustained pressure. The most striking development this week is the speed of the short retreat. Short interest dropped nearly 9.3% over seven days to 6.5%…
Snapshot as of 17 Aug 2026
Organon & Co. heads into its July 23 quarterly report with short sellers stepping back and options traders leaning more bullish than they have been in months — a notable setup for a stock that has spent much of the…
Organon & Co. heads into the back half of June with its most interesting tension in months: short sellers are cutting exposure at a meaningful clip even as the consensus view on the Street remains cautious. Short…
Organon & Co. arrives at its April 30 Q1 print riding one of the most dramatic recoveries in the pharmaceutical space — up 125% in a month and 42% in the past week alone — yet the analyst community remains firmly in…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for OGN — free to start on ORTEX.
Sign up for free →Open OGN on ORTEX